About the Company
Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio's first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation.
|Name||Ticker||Market Capitalization (USD M)||Revenue (USD M)||Price/Book||Price/Earning||Net Margin (%)|
|Conversion Labs Inc||CVLB||108548||35213||3.74||42.66||7.33|
|Royalty Pharma plc||RPRX||18925||2239||2.81||15.20||43.40|
|Organon & Co.||OGN||8844||7891||-4.56||5.07||22.06|
|ATAI Life Sciences N.V.||ATAI||2272||20||4.78||-10.40||-932.88|
|Usana Health Sciences Inc||USNA||2079||1254||4.73||14.98||11.09|
|Cronos Group Inc||CRON||1935||57||1.22||-13.40||-258.59|
|NRX Pharmaceuticals Inc||NRXP||1170||2321||0.45||5.05||9.91|
|Phathom Pharmaceuticals Inc||PHAT||964||6.54||-6.01||None|
|Intersect ENT Inc||XENT||893||103||21.65||-13.01||-66.55|
|Phibro Animal Health Corp.||PAHC||893||833||3.70||16.25||6.53|
|Edgewise Therapeutics Inc||EWTX||796||2.70||-29.55||None|
|Fulcrum Therapeutics Inc||FULC||711||15||8.62||-9.63||-481.07|
|Pliant Therapeutics Inc||PLRX||614||13||2.51||-7.16||-613.56|
|Cyteir Therapeutics Inc||CYT||596||3.20||-20.62||None|
|Urovant Sciences Ltd||UROV||503||-3.65||-3.08||None|
|Ikena Oncology Inc||IKNA||404||10||2.18||-7.38||-551.28|
|Provention Bio Inc||PRVB||377||2.53||-2.94||None|
|Rain Therapeutics Inc||RAIN||355||413||2.19||-11.66||123.20|
|Verrica Pharmaceuticals Inc||VRCA||325||12||6.58||-8.94||-301.45|
|Terns Pharmaceuticals Inc||TERN||252||1.40||-7.30||None|
|Adicet Bio Inc||ACET||251||9||1.09||-4.46||-603.06|
|Milestone Pharmaceuticals Inc||MIST||219||15||1.23||-7.37||-215.93|
|Kaleido Biosciences Inc||KLDO||184||1||4.11||-2.07||None|
|Citius Pharmaceuticals Inc||CTXR||179||2.24||-7.81||None|
|Aquestive Therapeutics Inc||AQST||142||42||-2.95||-2.21||-152.73|
|Eton Pharmaceuticals Inc||ETON||124||15||6.13||-10.10||-74.52|
|Osmotica Pharmaceuticals Plc||OSMT||122||190||2.37||-1.31||-47.85|
|Kala Pharmaceuticals Inc||KALA||119||11||1.53||-0.94||None|
|Xeris Biopharma Holdings Inc||XERS||111||34||12.19||-1.44||-248.46|
|Odonate Therapeutics Inc||ODT||110||1.39||-0.94||None|
|Anebulo Pharmaceuticals Inc||ANEB||101||7.83||-2.54||None|
|Opiant Pharmaceuticals Inc||OPNT||100||37||3.03||-96.15||-3.06|
|Aerpio Pharmaceuticals Inc||ARPO||99||15||2.98||-5.24||-28.77|
|Natural Alternatives Internati||NAII||80||179||1.07||7.90||6.03|
|India Globalization Capital In||IGC||67||0||2.45||-7.60||-981.18|
|VYNE Therapeutics Inc||VYNE||51||16||0.77||2.31||-554.66|
|Assertio Holdings Inc||ASRT||36||117||0.49||-0.63||-38.05|
|Dermata Therapeutics Inc||DRMA||36||-75.67||-7.32||None|
|Acasti Pharma Inc||ACST||33||0||1.43||-1.66||-611.47|
|Nabriva Therapeutics Plc||NBRV||29||12||0.88||-0.49||-452.55|
|Lexaria Bioscience Corp||LEXX||27||1||3.76||-6.95||-445.15|
|Bio-Path Holdings Inc||BPTH||26||0||1.19||-2.49||18.96|
|Reviva Pharmaceuticals Holding||RVPH||25||1.41||-4.08||None|
|Baudax Bio Inc||BXRX||25||1||-10.80||0.76||9.10|
|Trevi Therapeutics Inc||TRVI||23||1.64||-0.66||None|
|Timber Pharmaceuticals Inc||TMBR||20||0||8.75||0.67||-527.55|
|Hoth Therapeutics Inc||HOTH||19||1.64||-2.02||None|
|Sonoma Pharmaceuticals Inc.||SNOA||11||17||3.32||-2.16||-31.96|
During the last session, Baudax Bio Inc. (NASDAQ:BXRX)’s traded shares were 1.76 million. At the end of the trading day, the stock’s price was $0.58, reflecting an intraday gain of 5.66% or $0.03. The ...
In last trading session, Baudax Bio Inc. (NASDAQ:BXRX) saw 1.19 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.56 trading at -$0.01 or ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
MALVERN, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ...
MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings ...
Advisor Insights Personal Finance Market Volatility Retirement Planning Start Investing Save for College Best Investments See All ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
(MENAFN- GlobeNewsWire - Nasdaq) MALVERN, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing ...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...